Form 4: Cullinan Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 3,489 shares of common stock at $12.52 per share to cover personal income tax obligations.

Summary

• Jennifer Michaelson, the Chief Scientific Officer of Cullinan Therapeutics, sold 3,489 shares of common stock on December 12, 2024.
• The shares were sold at a price of $12.52 per share.
• This transaction was made to cover personal income tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Ms. Michaelson directly owns 104,453 shares of Cullinan Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no significant positive or negative implications for the company's outlook.

Industry Context

Sales of shares by company officers to cover tax obligations are a common occurrence and are not unusual.

Comparison to Industry Standards

• This type of transaction is typical for executives who receive stock-based compensation.
• Many companies in the biotech sector, such as Amgen, Regeneron, and Gilead, see similar transactions from their executives.
• These sales are often pre-planned to avoid any appearance of insider trading.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

Cullinan Therapeutics, stock sale, insider trading, Jennifer Michaelson, Chief Scientific Officer, tax obligations, restricted stock units